Trial Profile
Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus/Eucreas) and Sitagliptin (Januvia/Janumet) After Two Weeks.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FPG-VISIT
- Sponsors Novartis; Novartis Pharma
- 19 Sep 2014 Primary endpoint has been met (Fasting plasma glucose level after 14 days of treatment with vildagliptin is superior to sitagliptin), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Jul 2011 New trial record